Evaluating Clinical Evidence for FcRn-Targeted Therapies in MG

In this episode, ‘Evaluating Clinical Evidence for FcRn-Targeted Therapies in MG,’ the panel of neuromuscular experts explores clinical and longer-term findings across the FcRn-targeted treatment landscape. The discussion begins with the phase 3 Vivacity-MG3 study and longer-term extension experience with nipocalimab, focusing on sustained improvements in MG-ADL and QMG and the ability to maintain IgG reduction over extended treatment. Faculty place particular emphasis on minimal symptom expression, noting the distinction between reaching MSE at a single time point and sustaining that level of disease control over time. They also discuss corticosteroid tapering among patients who maintained clinical improvement.

The panel then turns to efgartigimod and the ADAPT-SC+ experience. Experts review the proportion of antibody-positive and antibody-negative participants who achieved minimal symptom expression while noting that the available analysis evaluates MSE differently from sustained-MSE assessments. This distinction prompts a broader discussion about whether future MG outcomes should place greater emphasis on the proportion of time a patient remains in a well-controlled state.

Finally, the faculty discuss rozanolixizumab and the rapid clinical improvements observed as early as the first week of treatment. Although speed of onset can be clinically meaningful, the panel notes that treatment selection also incorporates administration, timing, comorbidities, and patient preference. Together, the discussion illustrates how efficacy, durability, and practical treatment characteristics can provide different perspectives on FcRn therapy.

The next episode in this series, ‘Assessing Treatment Response with FcRn-Targeted Therapy in MG,’ features the panelists discussing how quickly response should emerge, what constitutes adequate disease control, and where corticosteroid reduction fits into the definition of success.